HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see…
‘X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom’s Macroglobulinemia’ -TradeHawk, Citing FDA Site
https://twitter.com/TradeHawk/status/1542897334085775360
This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.
Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
‘WSJ News Exclusive | FDA Planning to Allow Clinical Trials of Pig Organ Transplants’ – WSJ
https://www.wsj.com/articles/fda-said-to-plan-pig-organ-transplant-clinical-trials-11656622411
AstraZeneca Shares Data At EASL And ESMO World GI For IMFINZI Combinations In Patients With Liver And Biliary Tract Cancers
survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve
TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922